thiazoles has been researched along with osimertinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C; Liu, D; Song, Y; Tsui, ST; Wang, S | 1 |
| Liu, D; Song, Y; Wang, S; Yan, F | 1 |
| Jiang, Y; Li, Z; Wan, S; Wu, X; Yan, R; Zhang, J | 1 |
| Cameron, MD; Chen, T; Dahlberg, SE; De Clercq, DJH; Eck, MJ; Gero, TW; Gray, NS; Heppner, DE; Jang, J; Jänne, PA; Mushajiang, M; Park, E; Shin, BH; To, C; Wang, S; Wong, KK; Xu, M; Yang, A | 1 |
2 review(s) available for thiazoles and osimertinib
| Article | Year |
|---|---|
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Thiazoles | 2016 |
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Thiazoles | 2016 |
2 other study(ies) available for thiazoles and osimertinib
| Article | Year |
|---|---|
Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations.
Topics: Acrylamides; Allosteric Regulation; Aniline Compounds; Benzeneacetamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2019 |
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
Topics: Acrylamides; Allosteric Regulation; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Thiazoles; Xenograft Model Antitumor Assays | 2019 |